Background: As management and prevention strategies against COVID-19 evolve, it is still uncertain whether prior exposure to immune checkpoint inhibitors (ICIs) affects COVID-19 severity in patients with cancer. Methods: In a joint analysis of ICI recipients from OnCovid (NCT04393974) and European Society for Medical Oncology (ESMO) CoCARE...
-
2022 (v1)PublicationUploaded on: February 14, 2024
-
2022 (v1)Publication
Background: Fifteen percent of patients with cancer experience symptomatic sequelae, which impair post-COVID-19 outcomes. In this study, we investigated whether a proinflammatory status is associated with the development of COVID-19 sequelae. Methods: OnCovid recruited 2795 consecutive patients who were diagnosed with Severe Acute Respiratory...
Uploaded on: February 4, 2024